Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06513533Phase 2Recruiting

Dimethyl Fumarate in Adrenomyeloneuropathy

Role: lead

NCT04303416Phase 2Completed

Plasma Exchange With Albumin in AMN Patients

Role: lead

NCT03864523Phase 2Completed

Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy

Role: lead

NCT01495260Phase 2Completed

A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

Role: lead

All 4 trials loaded